Defensin-antigen fusion proteins

Details Defensin-antigen fusion proteins Defensin-antigen fusion proteins

2011-03-29

2011-03-29

Carlson, Karen Cochrane (Department: 1656)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S252300, C435S320100, C536S023100, C514S002600, C514S04400A, C530S350000

Reexamination Certificate

active

07915040

ABSTRACT:
The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.

REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 4704362 (1987-11-01), Itakura et al.
patent: 5989552 (1999-11-01), McKenzie et al.
patent: 6001649 (1999-12-01), Caput et al.
patent: 6562347 (2003-05-01), Kwak et al.
patent: 2003/0138452 (2003-07-01), Kwak et al.
patent: 2004/0110165 (2004-06-01), Kwak et al.
patent: 0706799 (1996-04-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 97/35008 (1997-09-01), None
patent: WO 98/01564 (1998-01-01), None
patent: WO 98/07833 (1998-02-01), None
patent: PCT/US99/05345 (1999-03-01), None
patent: WO 99/46392 (1999-09-01), None
patent: WO 00/78334 (2000-12-01), None
patent: PCT/US01/29075 (2001-09-01), None
International Search Report from prior PCT Application No. PCT/US2001/029074, 5 pp, (mailed Jul. 29, 2002).
Lofthouse et al., “Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumor antigen,”Vaccine15(14): 1586-1593 (1997).
Biragyn et al. “E. ColiExpressed Lymphoma IG Idiotype Antigen Fusion Proteins and Chimeric HBcAG Particles Bearing Tumor Epitopes”Cancer Biotherapy10(1):85 (Mar. 3, 1995).
Boon, “Toward a genetic analysis of tumor rejection antigens,”Advances in Cancer Res. 58:177-210, 1992.
Cocchi et al. “The V3 Domain of the HIV-1 gp120 Envelope Glycoprotein Is Critical for Chemokine-Mediated Blockade of Infection”Nature Medicine2(11):1244-7 (Nov. 1996.)
Hellstrom et al, “Can co-stimulated tumor immunity be therapeutically efficacious?”Immunol. Rev. 145:123-145(1995).
Kwak et al. “Idiotypes as Vaccines for the Treatment of B-Cell Malignancies”Immunotechnology2(4):268 (Nov. 1, 1996).
U.S. Appl. No. 09/646,028, filed Mar. 12, 1999, Kwak et al., Preliminary Amendment, Mar. 12, 2000.
U.S. Appl. No. 10/335,394, filed Dec. 31, 2002, Kwak et al., Preliminary Amendment, Dec. 31, 2002.
U.S. Appl. No. 10/335,394, filed Dec. 31, 2002, Kwak et al., Advisory Action, Jun. 9, 2006.
U.S. Appl. No. 10/335,394, filed Dec. 31, 2002, Kwak et al., Communication RE: Appeal/Notice of Abandonement, Apr. 26, 2007.
U.S. Appl. No. 10/380,927, filed Mar. 17, 2003, Kwak et al., Preliminary Amendment, Mar. 17, 2003.
Biragyn et al., “B-Cell Malignancies as a Model for Cancer Vaccines: From Prototype Protein to Next Generation Genetic Chemokine Fusions,”Immunological Reviews, Munksgaard, vol. 170, Aug. 1999, pp. 115-126.
Biragyn et al., “Genetic Fusion of Chemokines to a Self Tumor Antigen Induces Protective, T-Cell Dependent Antitumor Immunity-”Nature Biotechnology, Nature Publishing, U.S., vol. 17, No. 3, Mar. 1, 1999, pp. 253-258.
Agrawal et al. Cell-cycle kinetics and VSV-G pseudotyped retrovirus-mediated gene transfer in blood-derived CD34+cells.Exp. Hematol. 24:738-747 (1996).
Alvarez et al. A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients.Hum. Gene Ther. 8:229-242 (1997).
Arnon, ed.Synthetic VaccinesI:83-92 CRC Press, Inc., Boca Raton, FL (1987).
Baggiolini et al. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines.Adv. Immunol. 55:97-179 (1994).
Barbas et al. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem.PNAS89:4457-4461 (1992).
Belyakov et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge.Proc Natl Acad Sci USA. 95:1709-1714 (1998).
Belyakov et al. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.J Virol. 72(10):8264-8272 (1998).
Ben-Baruch et al. The differential ability of IL-8 and neutrophil-activating peptide-2 to induce attenuation of chemotaxis is mediated by their divergent capabilities to phosphorylate CXCR2 (IL-8 receptor B).J Immunol. 158:5927-5933 (1997).
Bergman et al. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin.Eur. J. Immunol. 7:413-417 (1977).
Biragyn et al. Mediators of innate Immunity that target immature, but not mature, dendritic cells induce antitumor Immunity when genetically fused with nonimmunogenic tumor antigens.J Immun167(11):6644-6653 (2001).
Blasi et al. Selective immortalization of murine macrophages from fresh bone marrow by araf/mycrecombinant murine retrovirus.Nature318:667-670 (1985).
Bonecchi et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s.J. Exp. Med. 187(1):129-134 (1998).
Brake et al. α-factor-directed synthesis and secretion of mature foreign proteins inSaccharomyces cerevisiae. PNAS81:4642-4646 (1984).
Bridges. Participation of the humoral immune system in the myeloma-specific transplantation resistance.J. Immunol. 121(2):479-483 (1978).
Buchner et al. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies.Analytical Biochem. 205:263-270 (1992).
Butcher. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity.Cell67:1033-1036 (1991).
Bystryn. Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens.Annals New York Academy of Sciences690:190-203 (1993).
Campbell et al. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor,Int. Rev. Immunol. 4:251-270 (1989).
Campbell et al. Idiotype vaccination against murine B cell lymphoma, Humoral and cellular requirements for the full expression of antitumor immunity.J. Immunol. 145(3):1029-1036 (1998).
Campbell et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.J. Immunol. 139(8):2825-2833 (1987).
Clark-Lewis et al. Structure-activity relationships of Interleukin-8 determined using chemically synthesized analogs: critical role of NH2-terminal residues and evidence for uncoupling neutrophil chemotaxis, exocytosis, and receptor binding activities.J. Biol. Chem. 266(34):23128-23134 (1991).
Crystal. Clinical protocol: Phase I study of direct administration of a replication deficient adenovirus vector containingE. colicytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine.Human Gene Therapy8:985-1001 (1997).
Daley et al. Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy.J. Immunol. 120(5):1620-1624 (1978).
Damon et al. Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog.Proc Natl Acad Sci USA. 95:6403-6407 (1998).
Davis et al. DNA-based immunization against hepatitis B surface antigen (HBsAg) in normal and HBsAg-transgenic mice.Vaccine15(8):849-852 (1997).
Dieu et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites.J Exp Med. 188(2):373-386 (1998).
Dilloo et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity.Nature Medicine2(10):1090-1095 (1996).
Dyke et a

Affiliated with

Also associated with

Rating

Defensin-antigen fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Defensin-antigen fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Defensin-antigen fusion proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2685727